Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Personalized medicine in ovarian cancer: Design and development of a tool for response prediction to targeted platinated nanocarrier-based treatments

Project description

Innovative tool for treatment response prognosis in ovarian cancer

Ovarian cancer stands out as the most lethal gynaecological malignancy due to its poor prognoses resulting from diagnoses made in advanced stages, vague symptoms, the absence of reliable screening tools and the development of treatment resistance. In this context, personalised treatments play a crucial role, necessitating improved therapeutic approaches and appropriate treatment selections. Addressing this challenge, the MSCA-funded OvaCTool project strives to create a highly sensitive tool based on mass cytometry. This tool is aimed at enhancing the prognosis of treatment responses to newly developed targeted nanocarriers used in platinum (Pt)-based chemotherapy for ovarian cancer. The project’s focus is on evaluating a range of iron-based nanocarriers for Pt (IV) prodrugs, specifically designed to target ovarian cancer cells.

Objective

Personalized treatments are considered major challenges in clinical practice. They become particularly critical for diseases with poor prognoses diagnosed at later stages, such as ovarian cancer. Here, the vague symptoms, the lack of reliable screening tools and the treatment resistances have made this cancer the most lethal gynaecological malignancy (40% 5-year survival rate; 50-90% recurrence rate). Thus, ovarian cancer patients would certainly benefit from improved therapies and appropriate treatment choices. In this regard, the present OvaCTool project aims at developing a highly sensitive mass cytometer-based tool for the prediction of treatment response against newly designed targeted nanocarriers for platinum (Pt)-based chemotherapy in ovarian cancer. Specifically, diverse iron-based nanocarriers for Pt (IV) prodrugs targeting ovarian cancer cells will be evaluated. Such assessment will also include the understanding of ovarian cancer proteome changes after therapy. All this information will then be integrated to define biomarkers of treatment response which will be combined in a mass cytometry panel (up to 50 markers) together with proteins to identify other cells from the tumour microenvironment aiming at the stratification of patients into responders vs non-responders to the newly designed drugs. Likewise, protein corona formation on the nanostructures will be investigated to recognize potential challenges after intravenous injection of the drug in the clinical setting. In summary, this project will provide potential enhanced anticancer drugs and a prediction tool for targeted treatment choices which will help towards better survival rates for this malignant disease.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2022-PF-01

See all projects funded under this call

Coordinator

UNIVERSIDAD DE OVIEDO
Net EU contribution
€ 181 152,96
Address
CALLE SAN FRANCISCO 3
33003 OVIEDO
Spain
Region
Noroeste Principado de Asturias Asturias
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data